`

DAFTAR PUSTAKA

[1] R. A. Collaborators, "Global, Regional, and National Burden of Rheumatoid Arthritis, 1990 – 2020, and Projections to 2050: a Systematic Analysis of the Global Burden of Disease Study 2021," *GBD*, vol. 5, no. October, 2023.

[2] WHO, "WHO," World of Health Organization. Accessed: Jan. 27, 2026.

[3] S. Safiri *et al.*, "Global, Regional and National Burden of Osteoarthritis 1990-2017: a Systematic Analysis of the Global Burden of Disease Study 2017.," *Ann. Rheum. Dis.*, vol. 79, no. 6, pp. 819–828, Jun. 2020.

[4] KEMENKES, *Riskesdas.* Lembaga Penelitian dan Pengembangan Kesehatan, 2019.

[5] Riskesdas, *Laporan Provinsi Jawa Tengah Riskesdas 2018*. 2018.

[6] J. S. Smolen, "Rheumatoid Arthritis Primer — Behind the Scenes," *Nat. Rev. Dis. Primers*, vol. 6, no. 1, p. 32, 2020.

[7] G. Noto *et al.*, "Pathogenesis of Rheumatoid Arthritis: One Year in Review 2025," *Clinical and Experience Rheumatology*, pp. 1533–1540, 2025.

[8] S. Park *et al.*, "Tm4sf19 Inhibition Ameliorates Inflammation and Bone Destruction in Collagen-Induced Arthritis by Suppressing TLR4-Mediated Inflammatory Signaling and Abnormal Osteoclast Activation," *Bone Res.*, vol. 13, no. 1, 2025.

[9] D. Wu *et al.*, "Systemic Complications of Rheumatoid Arthritis: Focus on Pathogenesis and Treatment," *Front. Immunol.*, vol. 13, no. December, pp. 1–13, 2022.

[10] J. S. Smolen *et al.*, Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs*: 2019.* vol. 79, no. 6. 2020.

[11] Z. Nagy, E. Szigedi, S. Takács, and N. Császár-Nagy, "The Effectiveness of Psychological Interventions for Rheumatoid Arthritis

(RA): A Systematic Review and Meta-Analysis," Mar. 01, 2023, *MDPI*.

[12] J. Piekarz, N. Picheta, J. Pobide, K. Dani, and P. Gil-kulik, "Phytotherapy as an Adjunct to the Treatment of Rheumatoid Arthritis," *Phytomedicine*, vol. 148, 2025.

[13] A. Kumar, S. Sreedharan, A. Kumar, and P. Singh, "a Review on Bioactive Phytochemicals and Ethnopharmacological Potential of Purslane (*Portulaca Oleracea* L.)," *Heliyon*, vol. 8, no. July 2021, p. e08669, 2022.

[14] H. S. Gupta, U. Rajashekhar, and D. K. Jha, "International Journal of Pharmaceutical Sciences and Drug Research Assessing the Effect of Portulaca oleracea Seed Extract for Alleviating Collagen Type-II Induced Arthritis in Female Wistar Rat," *International Journal of Pharmaceutical Sciences and Drug Research*, vol. 16, no. 2, pp. 163–170, 2024.

[15] B. Putra, R. N. Azizah, and E. M. Nopriyanti, "Efek Imunomodulator Ekstrak Etanol Herba Krokot (*Portulaca oleracea* L.) terhadap Tikus Putih (*Rattus norvegicus*) Jantan dengan Parameter Delayed Type Hypersensitivity (DTH)," *Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal)*, vol. 6, no. 1, pp. 20–25, 2020.

[16] J. Swarnkar, S. Prasad, K. Gupta, and P. Shrivastava, "Molecular Docking: In Silico Approach for Structure-Based Drug Designing Discovery," *J. Pharm. Negat.* vol. 13, no. 9, 2022.

[17] C. Rorai, F. Toschi, and I. Pagonabarraga, "Coexistence of Active and Hydrodynamic Turbulence in Two-Dimensional Active Nematics.," *Phys. Rev. Lett.*, vol. 129, no. 21, p. 218001, Nov. 2022.

[18] L. Shakeel, A. Shaukat, N. Khaliq, and A. Kashif, "Rheumatoid arthritis: a comprehensive overview of genetic markers, emerging therapies, and personalized medicine," *Annals of Medicine & Surgery*, 2025.

[19] Hidayat et al., "Diagnosis dan Pengelolaan Artritis Reumatoid, Perhimpunan Reumatologi Indonesia" 2021.

[20] H. Qian, C. Deng, S. Chen, X. Zhang, Y. He, and J. Lan, "Targeting Pathogenic Fibroblast - Like Synoviocyte Subsets in Rheumatoid Arthritis," *Arthritis Res. Ther.*, pp. 1–15, 2024.

[21] M. I. Edilova, A. Akram, and A. A. Abdul-sater, “ScienceDirect Innate Immunity Drives Pathogenesis of Rheumatoid Arthritis,” *Biomed. J.*, vol. 44, no. 2, pp. 172–182, 2020.

[22] Y. Gao, Y. Zhang, and X. Liu, “Rheumatoid Arthritis: Pathogenesis and Therapeutic Advances,” *MedComm (Beijing).*, no. August 2023, pp. 1–24, 2024.

[23] V. C. Romão and J. E. Fonseca, “Etiology and Risk Factors for Rheumatoid Arthritis: A State-of-the-Art Review,” *Front. Med.* vol. 8, no. November, pp. 1–20, 2021.

[24] Y. Ishikawa and C. Terao, “The Impact of Cigarette Smoking on Risk of Rheumatoid Arthritis: A Narrative Review.,” *Cells*, vol. 9, no. 2, Feb. 2020.

[25] X. Xie, X. Chen, X. Wang, S. Wang, and P. Qi, “Dual Regulatory Effects of Gut Microbiota and their Metabolites in Rheumatoid Arthritis: Balancing Pathogenic and Protective Mechanisms.,” *Front. Immunol.*, vol. 16, p. 1584023, 2025.

[26] S. Rayhaan, L. A. Hasan, R. Husain, A. A. Jasim, R. M. Hameed, and Z. R. Abdulhakeem, “Sex Hormones and Rheumatoid Arthritis: a Review of Their Role in Disease Development: Review Article,” *International Journal of Medical Science and Dental Health Page*, vol. 10, no. 08, pp. 62–75, 2024.

[27] A. V Poznyak *et al.*, “Rheumatoid Arthritis: What Inflammation Do We Face?” *Journal of Molecular Pathology*, pp. 454–465, 2024.

[28] A. D. Orazio *et al.*, “Pathogenesis of Rheumatoid Arthritis: One Year in Review 2024,” *Clin. Exp. Rheumatol.*, no. 5, pp. 1707–1713, 2024.

[29] C. Zhou, X. Cheng, and J. Zhang, “Research Advances of Pan-Immune Inflammation Value in Rheumatoid Arthritis,” *Front. Immunol.*, no. November, pp. 1–8, 2025.

[30] Y. Li *et al.*, “Exploring TNFR1: from Discovery to Targeted Therapy Development,” *J. Transl. Med.*, vol. 23, no. 1, 2025.

[31] E. S. Lee, H. J. Kim, D. Lee, and J. Y. Kang, “Rheumatoid Arthritis Severity is Mediated by Crosstalk Between Synoviocytes and Mature Osteoclasts Through a Calcium and Cytokine Feedback Loop,” *Exp. Mol. Med.*, no. March 2024, 2025.

[32] H. J. Kim, H. Kim, J. H. Lee, and C. Hwangbo, “Toll-Like receptor 4 (TLR4): New Insight Immune and Aging,” *Immunity & Ageing*, pp. 1–12, 2023.

[33] X. Wang *et al.*, “Dual-targeting inhibition of TNFR1 for Alleviating Rheumatoid Arthritis by a Novel Composite Nucleic Acid Nanodrug,” *Int. J. Pharm. X*, vol. 5, no. September 2022, p. 100162, 2023.

[34] N. Kondo, T. Kuroda, and D. Kobayashi, “Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis,” *International Journal of Molecular Science*, 2021.

[35] R. O. Williams, F. I. L. Clanchy, Y.-S. Huang, W.-Y. Tseng, and T. W. Stone, “TNFR2 Signalling in Inflammatory Diseases,” *Best Pract. Res. Clin. Rheumatol.*, vol. 38, no. 2, p. 101941, 2024, doi: https://doi.org/10.1016/j.berh.2024.101941.

[36] S. Shams *et al.*, “The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions,” *Front. Pharmacol.*, vol. 12, p. 680043, 2021.

[37] A. Hoffmann, G. Cheng, and D. Baltimore, “NF-κB : Master Regulator of Cellular Responses in Health and Disease,” *Immunity & Inflammation*, pp. 1–28, 2025.

[38] L. Cheng and X. Rong, “Clinical application of biological agents in rheumatoid arthritis,” *Transpl. Immunol.*, vol. 89, no. January, p. 102187, 2025.

[39] R. R. Lahmudin, “Studi Literatur Profil Farmakokinetik Obat Anti Inflamasi Nonsteroid Pada Populasi Geriatri: Literature,” *Jurnal Ilmiah dr. Aloei Saboe*, vol. 4, no. 1, pp. 84–95, 2024.

[40] A. Suparman, S. Wijayanti, and I. Novrianti, “Pola Penggunaan Obat Rheumatoid Arthritis pada Pasien Rheumatoid Arthritis di Poli Penyakit Dalam RSUD Dr. H . Jusuf SK Kota Tarakan Periode Januari –November 2024,” *Jurnal Kesehatan Tambusai*, vol. 6, pp. 3181–3189, 2025.

[41] M. A. Mulki *et al.*, “Tinjauan Literatur: Toksisitas Metotreksat Sebagai Antirheumatoid Arthritis,” *Jurnal Ilmiah Wahana Pendidikan*, vol. 9, no. 14, pp. 503–516, 2023.

[42] D. F. Rasool, H. R. Fatah, and E. K. M. Zangana, "Anti-Inflammatory and Immunomodulatory Effect of Purslane and Purslane and Turmeric in Rheumatoid Arthritis RAT Models," *Cellular and Molecular Biology Original*, 2025.

[43] J. V. S. Chandana, B. Neha, K. Sravani, S. Mujahid, and T. R. Rao, "An overview of Portulaca oleracea," *World Journal of Biology Pharmacy and Health Science*, vol. 22, no. March, pp. 445–459, 2025.

[44] Rianita and P. Murni, "Karakterisasi Morfologi dan Fenologi Pembungaan Krokot (*Portulaca oleracea* Linn.) Morphological," *Biospecies*, vol. 16, no. June, pp. 54–62, 2023.

[45] F. Ikman, D. Setiawan, and S. I. Aisyah, "Characterization of 13 Accessions of Purslane (*Portulaca sp.)* from Bogor, West Java, Indonesia," *J. Trop. Crop Sci.*, vol. 3, no. 3, pp. 67–74, 2016.

[46] V. Ghorani, S. Saadat, M. R. Khazdair, Z. Gholamnezhad, H. El-seedi, and M. H. Boskabady, "Immunoregulatory, and Antioxidant Effects of *Portulaca oleracea* L.," *Evidence-Based Complementary and Alternative Medicine*, vol. 2023, 2023.

[47] Y. Chie, L. Lucas, W. Tze, L. Su, E. Lau, and B. C. Tan, "Resilience of *Portulaca* Plants to Environmental Stresses and the Economic Potential of Their Bioactive Compounds". *Springer Berlin Heidelberg,* 2025.

[48] I. Ali, M. Ahmed, F. Aljuhaimi, M. Musa, Ö. Nurhan, and U. Emad, "Determination of The Distribution of Bioactive Compounds, Antioxidant Activities, Polyphenols and Macro and Microelement Contents In Different Parts of Wild and Cultivated Purslane (*Portulaca oleracea* L.) Plants," *Journal of Food Measurement and Characterization*, vol. 19, no. 5, pp. 3714–3724, 2025.

[49] S. Ghidouche and P. H. Ducrot, "Flavonoids: Hemisynthesis, Reactivity, Characterization and Free Radical Scavenging Activity," *Molecules*, pp. 2228–2258, 2017.

[50] W. J. Sun *et al.*, "Total Flavonoids of Abrus Cantoniensis Inhibit CD14/TLR4/NF-Kb/MAPK Pathway Expression and Improve Gut Microbiota Disorders to Reduce Lipopolysaccharide-Induced Mastitis in Mice," *Front. Microbiol.*, vol. 13, no. August, 2022.

[51] E. Johannes and Sjafaraenan, “Uji Sitotoksik dan Fitokimia Fraksi N-Heksan Ekstrak Batang dan Daun Krokot (Portulaca oleracea L),” *Bioma : Jurnal Biologi Makassar*, vol. 8, pp. 81–87, 2023.

[52] S. G. Husein, M. Sundalian, and N. Husna, “Review: Analisis Komponen Senyawa Kimia Krokot (Portulaca oleraceae L. dan Portulaca grandiflora Hook.),” *Jurnal Sains dan Kesehatan*, vol. 3, no. 2, pp. 317–327, 2021.

[53] W. A. Kartika, A. A. Silalahi, R. Rambe, F. Putra, and Fattara, “Molecular Docking Meniran (*Phillanthus niruri* L.),” *Indonesian Journal of Pharmaceutical and Clinical Research*, vol. 07, no. 02, pp. 14–24, 2024.

[54] Ekawati, Z. *Farmakologi Molekuler*. Yogyakarta: Gadjah Mada Universitiy Press, 2014.

[55] Q. Wu and S. Huang, “HCovDock : an Efficient Docking Method for Modeling Covalent Protein – Ligand Interactions,” *Brief. Bioinform.*, vol. 24, no. 1, pp. 1–12, 2023.

[56] I. I. Arief, T. M. Fakih, and T. A. Yuniarta, “Molecular Docking Senyawa Kuersetin sebagai Kandidat Antikanker Paru terhadap Target EGFR,” *Jurnal Riset Farmasi*, pp. 115–122, 2025.

[57] R. Wilujeng, E. Harlina, R. Madyastuti, and D. Andrianto, “Molecular Docking of the Bioactive Compound Physalis angulata as an Activator of Superoxide Dismutase 1,” *Indonesian Journal of Applied Research (IJAR)*, vol. 6, no. 2, pp. 67–75, 2025.

[58] Z. Ahmad and S. Amin, “Literatur Penggunaan Molecular Docking dalam Identifikasi Senyawa Potensial Sebagai Agen Anti- SARS-COV-2,” *Journal of Public Health Science (JoPHS)*, vol. 2, no. 2, pp. 230–238, 2025.

[59] M. Hafshah, I. M. Firdaus, I. N. Fitriani, and L. Rahmawati, “Jurnal Kimia Sains dan Aplikasi QSAR, Molecular Docking, and Molecular Dynamic of Novel Coumarin Derivatives as α -Glucosidase Inhibitor,” *Jurnal Kimia Sains dan Aplikasi*, vol. 27, no. 7, pp. 316–327, 2024.

[60] D. R. Fatmawati and Y. S. P. Inacahya, “Analisis Drug Likeness, Toksisitas Gusar , dan Docking Senyawa Antidesma Bunius sebagai Obat Hipokolesterolemik,” *Biocaster : Jurnal Kajian Biologi*, vol. 5, no. 3, pp. 442–460, 2025.

[61] T. K. Karami, S. Hailu, S. Feng, R. Graham, and H. J. Gukasyan, "Eyes on Lipinski's Rule of Five: A New 'Rule of Thumb' for Physicochemical Design Space of Ophthalmic Drugs," *Journal of Ocular Pharmacology and Therapeutics*, vol. 38, no. 1, pp. 43–55, 2022.

[62] S. Nhlapho, M. H. L. Nyathi, B. L. Ngwenya, and T. Dube, "Sciences of Pharmacy Druggability of Pharmaceutical Compounds Using Lipinski Rules with Machine Learning," *Science of Pharmacy*, vol. 5, no. 5, 2024.

[63] A. M. Anas, K. Sujatha, and R. Srimathi, "In-silico Estimation of Flavonoids through Molecular Docking and Assessment of ADMET properties as DPP-IV inhibitor in the treatment of Diabetes Mellitus," *Curr. Trends Biotechnol. Pharm.*, vol. 19, no. 3, pp. 2397–2410, 2025.

[64] T. Aprilianingtyas and H. Haryoto, "Aktivitas Antioksidan dari Ekstrak Etanol Herba Gelang Biasa (Portulaca oleracea L.) Dengan Metode DPPH, Frap, Dan Cuprac," *Usadha Journal of Pharmacy*, vol. 1, no. 3, pp. 364–374, 2022.

[65] Y. Lai *et al.*, "Recent Advances in the Translation of Drug Metabolism and Pharmacokinetics Science for Drug Discovery and Development," *Acta Pharm. Sin. B*, vol. 12, no. 6, 2022.

[66] P. Kumar, T. Kotra, and W. I. Lone, "Design, Synthesis and Antiproliferative Activity of Novel Colchicine Derivatives: Selective Inhibition of Melanoma Cell Proliferation," *Front. Pharmacol.*, no. June, pp. 1–13, 2025.

[67] Salman, Firawati, D. Setiawan, Nurasi, Muyazzidah, and S. Usman, *Farmakokinetika*. Purbalingga: Eureka Media Aksara, 2024.

[68] R. Rasida, Y. Dwi, M. Pinanga, A. H. Saputro, and S. Damayanti, "Komparasi Profil Admet Senyawa Sintetik dan Herbal Antimalaria: Pendekatan In Silico," *Acta Pharmaceutica Indonesia*, vol. 49, no. 2, pp. 85–98, 2024.

[69] M. Subhan, K. Sanachai, B. Sungthong, S. Datham, J. Ratha, and P. Puthongking, "Comparison in Vitro and in Silico Studies of Phenolic Acids and Flavonoids on α-Glucosidase Inhibition," *J. Pharm. Pharmacogn. Res.*, vol. 13, no. 1, pp. 311–323, 2025.

[70] E. R. Noordam, A. Wilapangga, and D. Rahmawati, "Analisis in Silico Potensi Farmakokinetik Senyawa Methyl salicylate 2-O- β -D-

glucopyranoside dari Ekstrak Daun Sirih Merah (*Piper crocatum*)," *Indonesian Journal of Pharmaceutical Education*, vol. 4, no. 2, pp. 317–324, 2024.

[71] D. A. M. Adnyaswari, A. W. Indrayani, and I. G. A. Artini, "In silico Toxicity and Pharmaceutical Properties to Get Candidates for Antitumor Drug," *J. Pharm. Res. Int.*, vol. 36, no. 2, pp. 1–11, 2024.

[72] R. Watanabe *et al.*, "Predicting Fraction Unbound in Human Plasma from Chemical Structure: Improved Accuracy in the Low Value Ranges," *Mol. Pharm.*, vol. 15, pp. 5302–5311, 2018.

[73] R. Ruswanto, R. Mardianingrum, and F. M. Naser, "Desain Dan Studi Interaksi Senyawa Kompleks Cobalt (Ii)-(1- Benzoyl-3-Methyl Thioureas) Dengan Dna Sebagai Kandidat Antikanker," *Pharmacoscript*, vol. 6, no. 2, pp. 152–163, 2023.

[74] H. M. Mashar *et al.*, *Interaksi Obat*. Eureka Media Aksara, 2023.

[75] J. Lipman, "The Long Walk to a Short Half-Life: the Discovery of Augmented Renal," *Journal of Antimicrobial Chemotherapy*, vol. 80, no. 12, pp. 3367–3374, 2025.

[76] S. Asano, A. Galetin, Y. Tomita, K. M. Giacomini, and X. Chu, "Predicting OCT2 / MATEs- Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies Perspectives from the International" *Clin. Pharmacol. Ther.*, vol. 118, no. 5, 2025.

[77] A. Furuhama *et al.*, "Evaluation of QSAR models for predicting mutagenicity: outcome of the Second Ames/QSAR international challenge project," *SAR QSAR Environ. Res.*, vol. 34, no. 12, pp. 983–1001, 2023.

[78] M. Mouadh, M. Ouassaf, N. Anede, S. Ullah, K. R. R. Rengasamy, and B. Y. Alhatlani, "Results in Chemistry In silico Study of Possible Marburg virus VP35 Inhibitors Using Structure Based Virtual Screening, ADMET, Stability Approach via DFT and Molecular Dynamics Simulations," *Results Chem.*, vol. 15, no. September 2024, p. 102278, 2025.

[79] G. Falcón-cano, A. Morales-helguera, H. Lambert, and C. Molina, "hERG Toxicity Prediction in Early Drug Discovery Using Extreme

Gradient Boosting and Isometric Stratified Ensemble Mapping," *Sci. Rep.*, pp. 1–14, 2025.

[80] J. Achar, J. W. Firman, and M. T. D. Cronin, "Conservative Consensus QSAR Approach for the Prediction of RAT Acute Oral Toxicity," *Computational Toxicology*, vol. 35, no. August, p. 100374, 2025.

[81] I. V. Ferrari, "Exploring Glucocorticoid Safety : Insights from pKCSM Predictions on Tolerability and Toxicity Profiles Exploring Glucocorticoid Safety: Insights from pKCSM Predictions on Tolerability and Toxicity Profiles," *Preprints (Basel).*, 2024.

[82] R. Geci, A. Zeynep, S. Stephan, and S. Lars, "Integration of In Vitro and In Silico Approaches Enables Prediction of Drug-Induced Liver Injury," *Arch. Toxicol.*, 2026.

[83] R. Zhang, H. Guo, Y. Hua, X. Cui, Y. Shi, and X. Li, "Ecotoxicology and Environmental Safety Modeling and insights into the Structural basis of chemical Acute Aquatic Toxicity," *Ecotoxicol. Environ. Saf.*, vol. 242, no. July, p. 113940, 2022.

[84] S. C.--associated Mucormycosis, O. Pokharkar, H. Lakshmanan, G. Zyryanov, and M. Tsurkan, "In Silico Evaluation of Antifungal Compounds from Marine," *Mar. Drugs*, 2022.

[85] Y. Banne, S. H. Gurning, A. Brata, F. Jannah, M. Si, and M. Sc, *Interaksi Obat*. Kendari: Perkumpulan Pendidikan dan Pelatihan Tenaga Kesehatan Progres Ilmiah Kesehatan, 2025.

[86] Siswandono, *Kimia Medisinal 1*. Surabaya: Airlangga University Press, 2016.

[87] S. R. Yende, V. D. Sannapuri, N. S. Vyawahare, and U. N. Harle, "Antirheumatoid Activity of Aqueous Extract of Piper Longum on Freunds Adjuvant-Induced Arthritis in Rats," *International Journal of Pharmaceutical Science and Research*, vol. 1, no. 9, p. 4, 2015.

[88] RSCB PDB, "PDB-101," Molecular explorations through biology and medicine. Accessed: Mar. 07, 2026.

[89] D. Liebschner, P. V. Afonine, N. W. Moriarty, B. K. Poon, V. B. Chen, and P. D. Adams, "CERES: A cryo-EM re-refinement system for continuous improvement of deposited models," *Acta Crystallogr. D Struct. Biol.*, vol. 77, pp. 48–61, 2021.

[90] C. Shao, H. Yang, J. D. Westbrook, J. Y. Young, C. Zardecki, and S. K. Burley, "Multivariate Analyses of Quality Metrics for Crystal Structures in the Protein Data Bank Archive," *Methods in Molecular Biology*, vol. 2305, no. 3, pp. 3–21, 2021.

[91] Y. S. Fadillah, M. F. Kurniawan, and T. Rohmayanti, "Analisis Molecular Docking Senyawa Ekstrak Seledri (*Apium Graveolens*) untuk Penghambatan Angiotensin-Converting Enzyme 2 Molecular," *Jurnal Agroindustri Halal ISSN*, vol. 5, no. April, pp. 57–66, 2023.

[92] A. Hakiki, A. Andika, and R. Rahmawati, "Studi Molecular Docking dan Prediksi ADMET Senyawa Turunan Kurkumin Sebagai Inhibitor Kasein Kinase 2-α," *Lumbung Farmasi: Jurnal Ilmu Kefarmasian*, vol. 5, no. 2, p. 195, 2024.

[93] J. Singh, K. L. Khanduja, and P. K. Avti, "Unravelling Benzazepines and Aminopyrimidine as Multi-Target Therapeutic Repurposing Drugs for EGFR V774M Mutation in Neuroglioma Patients," *BioImpacts*, vol. 14, no. 3, p. 28876, 2024.

[94] S. Samarpita, J. Y. Kim, M. K. Rasool, and K. S. Kim, "Investigation of Toll-Like Receptor (TLR) 4 Inhibitor TAK-242 as a New Potential Anti-Rheumatoid Arthritis Drug," *Arthritis Res. Ther.*, vol. 22, no. 1, pp. 1–10, 2020.

[95] S. Kwon and C. Seok, "CSAlign and CSAlign-Dock: Structure Alignment of Ligands Considering Full Flexibility and Application to Protein–Ligand Docking," *Comput. Struct. Biotechnol. J.*, vol. 21, pp. 1–10, 2023.

[96] A. U. Hanif, P. A. Lukis, and A. Fadlan, "Pengaruh Minimisasi Energi MMFF94 dengan MarvinSketch dan Open Babel PyRx pada Penambatan Molekular Turunan Oksindola Tersubstitusi," *Alchemy*, vol. 8, no. 2, pp. 33–40, 2020.

[97] P. W. Kenny, "Hydrogen-Bond Donors in Drug Design.," *J. Med. Chem.*, vol. 65, no. 21, pp. 14261–14275, Nov. 2022.

[98] R. R. R. Bahi and A. P. Gonibala, "Fitofarmaka," *Penerbit Widina Bhakti Persada Bandung*, vol. 2, 2023.

[99] I. Arief and Hairunnisa, "Profil ADME dari Entitas Molekul Baru yang Disetujui oleh FDA Tahun 2021: Suatu Kajian In Silico," *Jamb.J.Chem*, vol. 4, no. 2, pp. 1–11, 2022.

[100] M. Khudzaif, S. A. Kalsum, and A. Z. Nisak, "Molecular Docking Senyawa Flavonoid Daun Sirsak (Annona muricata L.) terhadap Reseptor Estrogen Alfa (RE-A) sebagai Kandidat Obat Antikanker Payudara," *Sains Medisina*, vol. 3, no. 1, pp. 1–9, 2024.

[101] S. T. Smith, L. Shub, and J. Meiler, "PlaceWaters: Real-time, explicit Interface Water Sampling during Rosetta Ligand Docking," *PLoS One*, vol. 17, no. 5 May, pp. 1–12, 2022.

[102] S. Falah, L. Ambarsari, D. Andrianto, R. Kurniasih, and S. Tachibana, "The potential of Myricitrin, a Flavonoid Compound in Eugenia polyantha from Indonesia, as an Antiviral Drug for SARS-Cov-2 through the Molecular Docking Analysis," *Jurnal Kimia Sains dan Aplikasi*, vol. 26, no. 5, pp. 166–177, 2023.

[103] N. L. P. Pramesti and N. P. L. Laksmiani, "Skrining Senyawa Aloesin pada Lidah Buaya (*Aloe vera* (L.) Burm.f.) sebagai Antikanker Prostat Secara In Silico," *Prosiding Workshop dan Seminar Nasional Farmasi*, vol. 1, no. 1, pp. 495–506, 2022.

[104] M. S. Aathi, C. Kumar, K. S. Prabhudesai, D. Shanmugarajan, and S. Idicula-Thomas, "Mapping of FSHR Agonists and Antagonists Binding Sites to Identify Potential Peptidomimetic Modulators," *Biochim. Biophys. Acta Biomembr.*, vol. 1864, no. 4, p. 183842, 2022.

[105] M. S. Saddala and H. Huang, "Identification of Novel Inhibitors for TNFα, TNFR1 and TNFα-TNFR1 Complex Using Pharmacophore-Based Approaches," *J. Transl. Med.*, vol. 17, no. 1, pp. 1–16, 2019.

[106] S. Xiao, P. Zhang, G. Zhang, W. Li, H. Lin, and X. Hu, "Inhibition of Toll-Like Receptor 4 Activation by Apigenin and Chrysin via Competition for Sites and Conformational Changes," *Int. J. Biol. Macromol.*, vol. 252, p. 126415, 2023.

[107] Y. X. Goh, J. Jalil, K. W. Lam, K. Husain, and C. M. Premakumar, "Genistein: A Review on its Anti-Inflammatory Properties," *Front. Pharmacol.*, vol. 13, no. January, pp. 1–23, 2022.

[108] R. Ferreira De Freitas and M. Schapira, "A systematic Analysis of Atomic Protein-Ligand Interactions in the PDB," *Medchemcomm*, vol. 8, no. 10, pp. 1970–1981, 2017.

[109] G. Simanullang, A. M. Rahayyu, N. A. Nabila, A. Hammami, and I. K. Wardani, "Molecular docking and pharmacokinetic prediction of isoniazid and curcumin compounds against N-acetyltransferase 2

(NAT2) protein," *Jurnal Ilmu Kefarmasian Indonesia*, vol. 23, no. 2, p. 305, 2025.

[110] D. Nemutlu Samur, A. Boyacı, and E. Maytalman, "Oridonin Attenuates TLR4-Driven Inflammation and Autophagy in LPS-Stimulated Enteric Glial Cells: an in Vitro and in Silico Analysis," *Front. Cell. Neurosci.*, vol. 20, no. January, pp. 1–14, 2026.

[111] K. D. Apriali, E. Triana, M. I. Farhani, A. Khoirunnisa, and Y. A. Nur'aini, "Studi Penambatan Molekul dan Prediksi ADMET Senyawa Metabolit Sekunder Tanaman Kelor (Moringa oleifera L.) sebagai Inhibitor BACE1," *Fitofarmaka: Jurnal Ilmiah Farmasi*, vol. 2, no. 1, pp. 306–312, 2022.